Gain Therapeutics Inc (GANX) Stock Price, Quote & News

Latest News on GANX

Dec 31, 2024, 12:23 PM EST - 17 days ago

Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results

Dec 23, 2024, 7:30 AM EST - 25 days ago

Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease

Dec 11, 2024, 8:30 AM EST - 5 weeks ago

Gain Therapeutics To Present At Biotech Showcase 2025

Oct 7, 2024, 7:00 AM EDT - 3 months ago

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024

Oct 3, 2024, 7:00 AM EDT - 3 months ago

Gain Therapeutics to Participate at Upcoming Investor Conferences

Sep 30, 2024, 7:00 AM EDT - 3 months ago

Gain Therapeutics Presents Phase 1 GT-02287 Data at International Congress of Parkinson's Disease and Movement Disorders Demonstrating Increase in GCase Activity in Healthy Volunteers

Sep 26, 2024, 7:00 AM EDT - 4 months ago

Gain Therapeutics To Host Virtual Webinar on Results From Phase 1 Study and Design of Upcoming Phase 1b Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Sep 19, 2024, 7:00 AM EDT - 4 months ago

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson's Disease Models Including Two Late-Breakers at Neuroscience 2024

Aug 29, 2024, 7:30 AM EDT - 5 months ago

Gain Therapeutics Announces Positive Topline Results from the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for Parkinson's Disease

Aug 8, 2024, 7:30 AM EDT - 5 months ago

Gain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update

Jul 9, 2024, 7:00 AM EDT - 6 months ago

Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease

Jul 1, 2024, 10:13 AM EDT - 7 months ago

Gain Therapeutics, Inc. (GANX) Special Call Transcript

Jun 28, 2024, 4:39 PM EDT - 7 months ago

Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

Jun 27, 2024, 4:08 PM EDT - 7 months ago

Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

Jun 27, 2024, 8:35 AM EDT - 7 months ago

Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson's disease

Jun 25, 2024, 7:00 AM EDT - 7 months ago

Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 13, 2024, 9:00 PM EDT - 7 months ago

Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

Jun 13, 2024, 4:44 PM EDT - 7 months ago

Gain Therapeutics Announces Proposed Public Offering

May 30, 2024, 7:00 AM EDT - 8 months ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024

May 29, 2024, 6:15 PM EDT - 8 months ago

Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential

May 14, 2024, 7:30 AM EDT - 8 months ago

Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update

Apr 24, 2024, 9:25 AM EDT - 9 months ago

Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Apr 8, 2024, 9:25 AM EDT - 10 months ago

Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

Apr 1, 2024, 9:25 AM EDT - 10 months ago

Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer

Mar 26, 2024, 8:00 AM EDT - 10 months ago

Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update

Mar 15, 2024, 2:30 PM EDT - 11 months ago

Gain Therapeutics to Present at Public Ventures Discovery Day

Mar 5, 2024, 8:00 AM EST - 11 months ago

Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson's Disease

Feb 27, 2024, 2:00 PM EST - 11 months ago

Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Feb 14, 2024, 12:29 PM EST - 1 year ago

Gain Therapeutics Announces 2024 R&D Update on Parkinson's Disease with KOL & Analyst Insight

Feb 6, 2024, 9:56 AM EST - 1 year ago

UPDATE - Gain Therapeutics' GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson's Disease

Jan 12, 2024, 6:49 PM EST - 1 year ago

Gain Therapeutics: The Case For GCase In Parkinson's And Buyout Potential

Jan 2, 2024, 8:00 AM EST - 1 year ago

Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024

Dec 22, 2023, 5:56 PM EST - 1 year ago

Doubling Down On Gain Therapeutics

Dec 1, 2023, 8:00 AM EST - 1 year ago

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Nov 29, 2023, 8:00 AM EST - 1 year ago

Gain Therapeutics to Participate in AI Driven Drug Discovery Summit

Nov 24, 2023, 1:01 PM EST - 1 year ago

Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option

Nov 21, 2023, 8:54 AM EST - 1 year ago

Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants

Nov 14, 2023, 7:00 AM EST - 1 year ago

Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update

Oct 4, 2023, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson's Disease

Sep 25, 2023, 4:05 PM EDT - 1 year ago

Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023

Sep 20, 2023, 4:05 PM EDT - 1 year ago

Gain Therapeutics to Present at the Cambridge Healthtech Institute's 2nd Annual Neurodegeneration Targets Conference

Sep 12, 2023, 9:25 AM EDT - 1 year ago

Gain Therapeutics Receives Approval to Commence Phase 1 Clinical Study of GT-02287 from the Human Research Ethics Committee (HREC) in Australia

Aug 28, 2023, 7:00 AM EDT - 1 year ago

Gain Therapeutics Presents New Preclinical Data Demonstrating a Reduction of Plasma Neurodegeneration Biomarker NfL after Administration of its Drug Candidate GT-02287 in GBA1 Parkinson's Disease Model

Aug 10, 2023, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update

Aug 7, 2023, 7:00 AM EDT - 1 year ago

Gain Therapeutics Announces Acceptance of Late Breaking Abstract for Presentation at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2023, 8:00 AM EDT - 1 year ago

Gain Therapeutics to Participate in the 2023 BTIG Virtual Biotechnology Conference

Jun 1, 2023, 8:00 AM EDT - 1 year ago

Gain Therapeutics to Present at the Jefferies Healthcare Conference

May 31, 2023, 5:55 AM EDT - 1 year ago

Gain Therapeutics: Undervalued Based On Drug Development Platform And Lead Parkinson's Asset

May 12, 2023, 8:00 AM EDT - 1 year ago

Gain Therapeutics Reports First Quarter 2023 Financial Results and Business Update

May 3, 2023, 9:15 AM EDT - 1 year ago

Market Cap	62.86M
Revenue (ttm)	60,000.00
Net Income (ttm)	-22.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-37,116.67%
Debt to Equity Ratio	0.06

Volume	272,700
Avg Vol	240,806
Day's Range	N/A - N/A
Shares Out	26.53M
Stochastic %K	47%
Beta	0.14
Analysts	Strong Sell
Price Target	$7.33